Literature DB >> 27630344

Survival Trends in Elderly Patients with Glioblastoma in the United States: a Population-based Study.

Binay Kumar Shah1, Amir Bista2, Sandhya Sharma2.   

Abstract

BACKGROUND/AIM: Concomitant and adjuvant temozolomide along with radiotherapy following surgery (the Stupp regimen) is the preferred therapy for young patients with glioblastoma as well as for elderly (>70 years) ones with favorable risk factors. This study investigated the survival trend since the introduction of the use of the Stupp regimen in elderly patients in a population-based setting.
MATERIALS AND METHODS: Surveillance, Epidemiology, and End Results 18 database was used to identify patients aged ≥70 years with glioblastoma as the first primary cancer diagnosed from 1999 to 2010. Chi-square test, Kaplan-Meier analysis with log-rank test and Cox proportional hazard method were used for analysis. RESULT: A total of 5,575 patients were included in the survival analysis. Survival in Stupp era (year of diagnosis ≥2005) was significantly better compared to the pre-Stupp era with p<0.001 by log-rank test, with 1-, 2- and 3-year overall survival of 18.8% vs. 12.9%, 6.5% vs. 2.1% and 3.1% vs. 0.9% respectively, and hazard ratio for death in 3 years in the Stupp era was 0.87 (95% confidence interval=0.82-0.92; p<0.001) when compared with the pre-Stupp era. Factors such as younger age (<85 years), female sex, married status, Caucasian race and total resection favored better survival compared to their counterparts.
CONCLUSION: This study shows that the survival of elderly patients with glioblastoma has improved since the introduction of the Stupp regimen. However, there are significant differences in survival rates among various cohorts. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Glioblastoma; SEER; Stupp regimen; radiotherapy; survival

Mesh:

Substances:

Year:  2016        PMID: 27630344     DOI: 10.21873/anticanres.11052

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Sex as a biological variable in response to temozolomide.

Authors:  Luke Russell; Chelsea Bolyard; Yeshavanth Banasavadi-Siddegowda; Alex Weiss; Jianying Zhang; Reena Shakya; Kimerly Powell; Balveen Kaur
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

2.  Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland.

Authors:  Miikka Korja; Rahul Raj; Karri Seppä; Tapio Luostarinen; Nea Malila; Matti Seppälä; Hanna Mäenpää; Janne Pitkäniemi
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

Review 3.  The effect of race on the prognosis of the glioblastoma patient: a brief review.

Authors:  Nitesh P Patel; Kristopher A Lyon; Jason H Huang
Journal:  Neurol Res       Date:  2019-07-04       Impact factor: 2.448

4.  Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

Authors:  Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana
Journal:  J Neurooncol       Date:  2020-03-09       Impact factor: 4.130

5.  Rotating Gamma System Irradiation: A Promising Treatment for Low-grade Brainstem Gliomas.

Authors:  Pham Cam Phuong; Nguyen Quang Hung; Tran Bao Ngoc; Dirk Rades; Mai Trong Khoa
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

6.  Real-world evaluation of the impact of radiotherapy and chemotherapy in elderly patients with glioblastoma based on age and performance status.

Authors:  Karine A Al Feghali; Samantha M Buszek; Hesham Elhalawani; Neil Chevli; Pamela K Allen; Caroline Chung
Journal:  Neurooncol Pract       Date:  2020-10-14

7.  Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways.

Authors:  Vladimir N Ivanov; Jinhua Wu; Tom K Hei
Journal:  Oncotarget       Date:  2017-05-27

8.  The association between race and survival in glioblastoma patients in the US: A retrospective cohort study.

Authors:  Andrew Bohn; Alexander Braley; Pura Rodriguez de la Vega; Juan Carlos Zevallos; Noël C Barengo
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

9.  Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study.

Authors:  Amro K Bin Abdulrahman; Khalid A Bin Abdulrahman; Yousef R Bukhari; Abdulaziz M Faqihi; Juan Gabriel Ruiz
Journal:  Brain Behav       Date:  2019-08-29       Impact factor: 2.708

10.  Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.

Authors:  J Biau; E Chautard; E De Schlichting; G Dupic; B Pereira; A Fogli; M Müller-Barthélémy; P Dalloz; T Khalil; A F Dillies; X Durando; C Godfraind; P Verrelle
Journal:  Radiat Oncol       Date:  2017-12-06       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.